Shares of Athersys Inc. (NASDAQ:ATHX) were down 1.4% on Tuesday . The company traded as low as $2.11 and last traded at $2.12, with a volume of 162,584 shares traded. The stock had previously closed at $2.15.

A number of analysts have recently weighed in on ATHX shares. Maxim Group reaffirmed a “buy” rating on shares of Athersys in a research note on Sunday, May 8th. TheStreet raised shares of Athersys from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st. Finally, Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a research note on Monday, July 11th.

The company’s 50 day moving average is $2.20 and its 200-day moving average is $2.02. The firm has a market capitalization of $183.07 million and a price-to-earnings ratio of 217.00.

Athersys (NASDAQ:ATHX) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.14. The firm earned $15.45 million during the quarter, compared to the consensus estimate of $1.85 million. Athersys’s revenue for the quarter was up 2016.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.16) earnings per share. On average, equities research analysts predict that Athersys Inc. will post ($0.23) EPS for the current year.

In other Athersys news, COO William Lehmann, Jr. sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $2.17, for a total transaction of $54,250.00. Following the transaction, the chief operating officer now directly owns 279,017 shares in the company, valued at approximately $605,466.89. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.